search
Back to results

P.E.M.F. Therapy of Chronic Wounds

Primary Purpose

Chronic Wounds

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Pulsed ElectroMagnetic Field (PEMF) therapy
Pulsed ElectroMagnetic (PEMF) therapy
Sponsored by
PEMF Systems, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Wounds focused on measuring wounds, chronic

Eligibility Criteria

21 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  • Age must be at least 21 years old at the time of signing consent. 8.2 The index study ulcer size must be between 2.0 and 30.0 cm2 at the time of randomization. Measurements and photographs will to be taken after sharp debridement if performed at the Randomization Visit.
  • The index ulcer must have been present for at least 6 weeks prior to randomization.
  • If more than one ulcer is present on the target limb, the largest eligible ulcer should be deemed the study ulcer. Other ulcers close to the study ulcer are allowed and may be of any size. However, they should be > 2cm away from the study ulcer. Ulcers are allowed at other locations such as the on the contralateral limb. Other ulcers present besides the index study wound can be treated with different local care but cannot be treated with the PEMF device.
  • Only one site of application of the PEMF device is allowed and the PEMF device must be placed directly over the study ulcer.
  • Subjects to be enrolled into the VLU group must have had a duplex ultrasound study (if not done within six months prior the first screening visit) to document venous disease (deep system obstruction or reflux > 0.5 sec, or superficial system reflux > 0.5 sec, or have the characteristic hyperpigmentation and skin changes (lipodermatosclerosis) typical of venous disease.
  • Diabetic Foot Ulcer (DFU): Subjects should have with neuropathy demonstrated by monofilament testing and have Wagner grade 1 wounds without involvement of tendon, bone, or joint.
  • Pressure Ulcer (PU): PU subject wounds must be stage 3 without deep structure involvement such as bone, tendon, or joint.

Exclusion Criteria

  • Wounds due to autoimmune disease such as rheumatoid arthritis or vasculitis.
  • Exposed structures deep to the adipose layer of skin such as muscle, fascia, tendon, joint, or bone.
  • The presence of sinus tracts that have not been sufficiently marsupialized such that the wound depth cannot be assessed by gross visual inspection is an exclusion.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Sham Comparator

    Arm Label

    PEMF low power

    PEMF medium power

    PEMF Sham control

    Arm Description

    PEMF therapy using a device with low pulse intensity.

    PEMF therapy using a medium pulse intensity.

    Control arm using a sham PEMF device.

    Outcomes

    Primary Outcome Measures

    Time to complete healing
    Complete re-epithelization of wound
    Wound closure
    Squared milimeters of wound closure

    Secondary Outcome Measures

    Number and type of adverse events
    Safety Endpoint
    Device effectiveness
    Compare the rate of effectiveness between performance of the two PEMF power levels by measuring percentage of wound closure

    Full Information

    First Posted
    July 13, 2022
    Last Updated
    August 29, 2022
    Sponsor
    PEMF Systems, Inc.
    Collaborators
    VA Long Beach Healthcare System, Southern California Institute for Research and Education
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05493943
    Brief Title
    P.E.M.F. Therapy of Chronic Wounds
    Official Title
    P.E.M.F. Therapy of Chronic Wounds
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 15, 2022 (Anticipated)
    Primary Completion Date
    December 15, 2023 (Anticipated)
    Study Completion Date
    December 15, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    PEMF Systems, Inc.
    Collaborators
    VA Long Beach Healthcare System, Southern California Institute for Research and Education

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Device Product Not Approved or Cleared by U.S. FDA
    Yes
    Product Manufactured in and Exported from the U.S.
    Yes

    5. Study Description

    Brief Summary
    To measure the effectiveness of pulsed electromagnetic fields (PEMF) as an adjunct wound care therapy.
    Detailed Description
    The goal of the three-arm trial is to employ application of pulsed electromagnetic fields (PEMF) directly over chronic wounds combined with standard of care local wound therapy (SOC). Three different PEMF devices, one a low power system (LP-PEMF), another a high power system (HP-PEMF) and the third a sham device that does not emit energy (S-PEMF) will be employed as adjuncts to standard wound care. The primary hypothesis to be tested is that exposure of wounds to one of the PEMF devices leads to significantly better and faster healing than the sham system. Research Design: An investigator initiated, prospective, double blinded parallel three arm treatment study. Subjects are randomized to receive one of the three PEMF devices (LP-PEMF, HP-PEMF or sham device) twice daily for 15 minutes directly over a wound. Initially, 40 subjects from each treatment group will be enrolled for total of 120 subjects at VA Long Beach Healthcare System (VALB) at the interim analysis. Based on the results of that analysis, one of the treatment arms will be eliminated and a follow-up study will continue with the remaining two arms. Additional 60 to 100 subjects are to be enrolled after interim analysis and the study may expand to Greater Los Angeles Medical Center. The study is expected to last 2 years. Participating eligible subjects will be asked to come to the VALB once a week for 14 weeks and then for 2 or 3 visits over 8 more weeks. The total number of visits including the first visit could be up to 17 visits in 5 months. The study has three phases: Screening phase (2 weeks); Treatment phase (12 weeks); and Follow-up phase (8 weeks). Subjects participation in the study may last up to 22 weeks, but subjects who heal early during the Treatment phase will have a reduced period of participation based on when their wound heals. Methodology Inclusion criteria include age ≥21 years; presence of venous leg ulcers (VLU), Diabetic foot ulcers (DFU) or Pressure Ulcers (PU); wound size between 2 and 30 cm2; no exposed joint, tendon or bone, no tunneling or sinus tracts; wound duration ≥ 6 weeks. Each wound will be reviewed for eligibility by assessing with duplex ultrasound, skin changes, tendon/bone/joint involvement, Ankle brachial Pressure Index (ABI), BMI, Hemoglobin A1c, Albumin and other medical history. Female subjects who are currently breast feeding or capable of conceiving and all males capable of insemination must use an acceptable form of contraception in order to participate in the study (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women). Findings: None Clinical Significance: Potentially beneficial treatment option for veterans with diabetic foot ulcer, venous leg ulcers or pressure ulcers.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Wounds
    Keywords
    wounds, chronic

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    3 arms, 2 have PEMF devices, 1 Control with sham devices
    Masking
    ParticipantCare Provider
    Masking Description
    Random, at time of enrollment
    Allocation
    Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    PEMF low power
    Arm Type
    Active Comparator
    Arm Description
    PEMF therapy using a device with low pulse intensity.
    Arm Title
    PEMF medium power
    Arm Type
    Active Comparator
    Arm Description
    PEMF therapy using a medium pulse intensity.
    Arm Title
    PEMF Sham control
    Arm Type
    Sham Comparator
    Arm Description
    Control arm using a sham PEMF device.
    Intervention Type
    Device
    Intervention Name(s)
    Pulsed ElectroMagnetic Field (PEMF) therapy
    Intervention Description
    Application of PEMF using treatment coils in eproximity to the area where treatment is desired.
    Intervention Type
    Other
    Intervention Name(s)
    Pulsed ElectroMagnetic (PEMF) therapy
    Intervention Description
    Control arm.
    Primary Outcome Measure Information:
    Title
    Time to complete healing
    Description
    Complete re-epithelization of wound
    Time Frame
    12 weeks
    Title
    Wound closure
    Description
    Squared milimeters of wound closure
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Number and type of adverse events
    Description
    Safety Endpoint
    Time Frame
    12 weeks
    Title
    Device effectiveness
    Description
    Compare the rate of effectiveness between performance of the two PEMF power levels by measuring percentage of wound closure
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    21 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria Age must be at least 21 years old at the time of signing consent. 8.2 The index study ulcer size must be between 2.0 and 30.0 cm2 at the time of randomization. Measurements and photographs will to be taken after sharp debridement if performed at the Randomization Visit. The index ulcer must have been present for at least 6 weeks prior to randomization. If more than one ulcer is present on the target limb, the largest eligible ulcer should be deemed the study ulcer. Other ulcers close to the study ulcer are allowed and may be of any size. However, they should be > 2cm away from the study ulcer. Ulcers are allowed at other locations such as the on the contralateral limb. Other ulcers present besides the index study wound can be treated with different local care but cannot be treated with the PEMF device. Only one site of application of the PEMF device is allowed and the PEMF device must be placed directly over the study ulcer. Subjects to be enrolled into the VLU group must have had a duplex ultrasound study (if not done within six months prior the first screening visit) to document venous disease (deep system obstruction or reflux > 0.5 sec, or superficial system reflux > 0.5 sec, or have the characteristic hyperpigmentation and skin changes (lipodermatosclerosis) typical of venous disease. Diabetic Foot Ulcer (DFU): Subjects should have with neuropathy demonstrated by monofilament testing and have Wagner grade 1 wounds without involvement of tendon, bone, or joint. Pressure Ulcer (PU): PU subject wounds must be stage 3 without deep structure involvement such as bone, tendon, or joint. Exclusion Criteria Wounds due to autoimmune disease such as rheumatoid arthritis or vasculitis. Exposed structures deep to the adipose layer of skin such as muscle, fascia, tendon, joint, or bone. The presence of sinus tracts that have not been sufficiently marsupialized such that the wound depth cannot be assessed by gross visual inspection is an exclusion.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Michael Davis
    Phone
    818-943-5414
    Email
    JMDavis@pemfsystems.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Christine Ma, MD, MPH
    Phone
    562-826-8000
    Ext
    1-2889
    Email
    Christine.Ma@va.gov
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ian Gordon, MD, PhD
    Organizational Affiliation
    VA Long Beach Healthcare System
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    17519258
    Citation
    Fernandez MI, Watson PJ, Rowbotham DJ. Effect of pulsed magnetic field therapy on pain reported by human volunteers in a laboratory model of acute pain. Br J Anaesth. 2007 Aug;99(2):266-9. doi: 10.1093/bja/aem129. Epub 2007 May 22.
    Results Reference
    background
    PubMed Identifier
    7546114
    Citation
    Salzberg CA, Cooper-Vastola SA, Perez F, Viehbeck MG, Byrne DW. The effects of non-thermal pulsed electromagnetic energy on wound healing of pressure ulcers in spinal cord-injured patients: a randomized, double-blind study. Ostomy Wound Manage. 1995 Apr;41(3):42-4, 46, 48 passim.
    Results Reference
    background
    PubMed Identifier
    9394172
    Citation
    Sarma GR, Subrahmanyam S, Deenabandhu A, Babu CR, Madhivathanan S, Kesavaraj N. Exposure to pulsed magnetic fields in the treatment of plantar ulcers in leprosy patients--a pilot, randomized, double-blind, controlled clinical trial. Indian J Lepr. 1997 Jul-Sep;69(3):241-50.
    Results Reference
    background
    PubMed Identifier
    25343187
    Citation
    Bragin DE, Statom GL, Hagberg S, Nemoto EM. Increases in microvascular perfusion and tissue oxygenation via pulsed electromagnetic fields in the healthy rat brain. J Neurosurg. 2015 May;122(5):1239-47. doi: 10.3171/2014.8.JNS132083. Epub 2014 Oct 24.
    Results Reference
    background
    PubMed Identifier
    24395219
    Citation
    Cheing GL, Li X, Huang L, Kwan RL, Cheung KK. Pulsed electromagnetic fields (PEMF) promote early wound healing and myofibroblast proliferation in diabetic rats. Bioelectromagnetics. 2014 Apr;35(3):161-9. doi: 10.1002/bem.21832. Epub 2014 Jan 3.
    Results Reference
    background
    PubMed Identifier
    24895156
    Citation
    Hannemann PF, Mommers EH, Schots JP, Brink PR, Poeze M. The effects of low-intensity pulsed ultrasound and pulsed electromagnetic fields bone growth stimulation in acute fractures: a systematic review and meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg. 2014 Aug;134(8):1093-106. doi: 10.1007/s00402-014-2014-8. Epub 2014 Jun 4.
    Results Reference
    background
    PubMed Identifier
    18536960
    Citation
    Matic M, Lazetic B, Poljacki M, Djuran V, Matic A, Gajinov Z. Influence of different types of electromagnetic fields on skin reparatory processes in experimental animals. Lasers Med Sci. 2009 May;24(3):321-7. doi: 10.1007/s10103-008-0564-0. Epub 2008 Jun 7.
    Results Reference
    background
    PubMed Identifier
    1390143
    Citation
    Stiller MJ, Pak GH, Shupack JL, Thaler S, Kenny C, Jondreau L. A portable pulsed electromagnetic field (PEMF) device to enhance healing of recalcitrant venous ulcers: a double-blind, placebo-controlled clinical trial. Br J Dermatol. 1992 Aug;127(2):147-54. doi: 10.1111/j.1365-2133.1992.tb08047.x.
    Results Reference
    background
    Links:
    URL
    https://pubmed.ncbi.nlm.nih.gov/17519258/
    Description
    Related Info
    URL
    https://pubmed.ncbi.nlm.nih.gov/7546114/
    Description
    Related Info
    URL
    https://pubmed.ncbi.nlm.nih.gov/9394172/
    Description
    Related Info
    URL
    https://pubmed.ncbi.nlm.nih.gov/25343187/
    Description
    Related Info
    URL
    https://pubmed.ncbi.nlm.nih.gov/24395219/
    Description
    Related Info
    URL
    https://pubmed.ncbi.nlm.nih.gov/24895156/
    Description
    Related Info
    URL
    https://pubmed.ncbi.nlm.nih.gov/18536960/
    Description
    Related Info
    URL
    https://pubmed.ncbi.nlm.nih.gov/1390143/
    Description
    Related Info

    Learn more about this trial

    P.E.M.F. Therapy of Chronic Wounds

    We'll reach out to this number within 24 hrs